Bevacizumab is safe in combination with chemotherapy for advanced non-squamous non-small cell lung cancer

July 19, 2010

Researchers have confirmed the safety of treating advanced non-squamous non-small-cell lung cancer with bevacizumab in combination with chemotherapy. Crucially, this study, published Online First in The Lancet Oncology, did not uncover any new safety signals than found previously. The Article is by Prof Lucio Crinň at the Hospital Santa Maria della Misericordia, Perugia, Italy and colleagues, did not uncover any new safety signals than found previously.

As well as laying to rest any concerns there have been about the toxicity of such treatment, these findings are especially important because phase 4 studies are done in a broader patient population that better mirrors the realities of clinical practice than phase 3 studies. Crinň et al have now shown that the main previously known toxicities, including life-threatening effects such as bleeding, do not seem to be any more common in this broader population. The scale of this comprehensive study that spans 40 centres also means that it was well suited to assess toxicities, and look for rare but serious new safety signals.

Advanced non-small-cell (NSCLC) is one of the most common types of cancer, and kills 1•18 million people every year. is a monoclonal antibody that blocks vascular endothelial growth factor A (VEGF-A), which stimulates the growth of new blood vessels. Thus, the antibody is a useful adjunct to chemotherapy, and it has shown meaningful activity in combination with chemotherapy in two different phase 3 studies.

Prof Lucio Crinň at the Hospital Santa Maria della Misericordia, Perugia, Italy and colleagues recruited 2212 patients with advanced or recurrent non-squamous NSCLC from 40 countries across six continents. They were given 7•5 or 15•0 mg/kg of bevacizumab every 3 weeks, plus standard chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression.

There were few clinically significant (grade ≥3) adverse events. For example, only 1% (15 patients) had pulmonary haemorrhage and 4% (80 patients) had bleeding. Overall, 57 (3%) patients died because of adverse events, with thromboembolism (26 patients, 1%) and bleeding (17, 1%) as the most common causes. The most common grade 3 or higher serious adverse events that the investigators judged to be associated with bevacizumab were pulmonary embolism (28 patients; 1%) and epistaxis, neutropenia, febrile neutropenia, and deep vein thrombosis (all of which occurred in 13 patients [1%]).

The authors say: "The study findings confirm the well established and manageable safety profile of bevacizumab, add to the efficacy evidence supporting the use of bevacizumab in first-line treatment, and establish the relevance of findings from randomised phase 3 studies to treatment with bevacizumab in a clinical practice setting."

They conclude: "The results of the SAiL study show that first-line bevacizumab in combination with standard regimens and continued until disease progression has an acceptable and manageable safety profile, with no new safety signals reported, and offers clinical benefit to patients with advanced or recurrent non-squamous NSCLC."

In an accompanying Comment, Robert Pirker at the Medical University of Vienna, Austria, describes the findings as "reassuring", and says that "careful patient selection according to the criteria used in SAiL and surveillance during treatment should guarantee the safe use of bevacizumab in routine practice."

PIrker says that the next challenge is to establish the drug's effect on survival through randomised trials.

"Other important issues regarding bevacizumab remain the optimum dose, the contribution of maintenance treatment to the overall benefit, and the characterisation of a clinically useful biomarker," he adds.

Related Stories

Recommended for you

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jul 20, 2010
"followed by single-agent bevacizumab until disease progression."
In other words, the patients died.
Was there any reduction of overall mortality at all??
not rated yet Jul 20, 2010
this is a terminal cancer - you wouldn't expect any reduction in mortality with this treatment. the goal is simply to extend life. arguably bevacizumab is a pretty expensive way to get someone a few extra months, but it is progress

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.